FR2861073B1 - Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique - Google Patents

Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique

Info

Publication number
FR2861073B1
FR2861073B1 FR0312142A FR0312142A FR2861073B1 FR 2861073 B1 FR2861073 B1 FR 2861073B1 FR 0312142 A FR0312142 A FR 0312142A FR 0312142 A FR0312142 A FR 0312142A FR 2861073 B1 FR2861073 B1 FR 2861073B1
Authority
FR
France
Prior art keywords
alkyl
cycloalkyl
benzamide derivatives
piperidinylmethyl
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0312142A
Other languages
English (en)
French (fr)
Other versions
FR2861073A1 (fr
Inventor
Gihad Dargazanli
Bouhtou Genevieve Estenne
Florence Medaisko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0312142A priority Critical patent/FR2861073B1/fr
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Priority to RU2006116887/04A priority patent/RU2351596C2/ru
Priority to ES04791552T priority patent/ES2287782T3/es
Priority to BRPI0415452-5A priority patent/BRPI0415452A/pt
Priority to PCT/FR2004/002641 priority patent/WO2005037781A2/fr
Priority to NZ547165A priority patent/NZ547165A/en
Priority to CNB2004800338737A priority patent/CN100430394C/zh
Priority to CA002542370A priority patent/CA2542370A1/fr
Priority to DK04791552T priority patent/DK1680418T3/da
Priority to PT04791552T priority patent/PT1680418E/pt
Priority to HR20070327T priority patent/HRP20070327T3/xx
Priority to PL04791552T priority patent/PL1680418T3/pl
Priority to AU2004281215A priority patent/AU2004281215B2/en
Priority to MEP-220/08A priority patent/MEP22008A/xx
Priority to AT04791552T priority patent/ATE361923T1/de
Priority to KR1020067007372A priority patent/KR20060087598A/ko
Priority to EP04791552A priority patent/EP1680418B1/fr
Priority to HK07104622.1A priority patent/HK1098456B/xx
Priority to SI200430375T priority patent/SI1680418T1/sl
Priority to DE602004006431T priority patent/DE602004006431T2/de
Priority to JP2006534798A priority patent/JP4696069B2/ja
Priority to YUP-2006/0316A priority patent/RS20060316A/sr
Publication of FR2861073A1 publication Critical patent/FR2861073A1/fr
Application granted granted Critical
Publication of FR2861073B1 publication Critical patent/FR2861073B1/fr
Priority to IL174941A priority patent/IL174941A/en
Priority to MA28942A priority patent/MA28097A1/fr
Priority to US11/405,170 priority patent/US7335670B2/en
Priority to NO20062151A priority patent/NO20062151L/no
Priority to ZA200603941A priority patent/ZA200603941B/en
Priority to CY20071101037T priority patent/CY1106786T1/el
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0312142A 2003-10-17 2003-10-17 Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique Expired - Fee Related FR2861073B1 (fr)

Priority Applications (28)

Application Number Priority Date Filing Date Title
FR0312142A FR2861073B1 (fr) 2003-10-17 2003-10-17 Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
KR1020067007372A KR20060087598A (ko) 2003-10-17 2004-10-15 Ｎ-[헤테로아릴(피페리딘-2-일)메틸]벤즈아미드의 유도체,그의 제조 방법 및 치료법에서의 그의 용도
BRPI0415452-5A BRPI0415452A (pt) 2003-10-17 2004-10-15 derivados de n-[heteroaril(piperidin-2-il)metil] benzamida, sua preparação e sua aplicação em terapêutica
PCT/FR2004/002641 WO2005037781A2 (fr) 2003-10-17 2004-10-15 Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
NZ547165A NZ547165A (en) 2003-10-17 2004-10-15 Derivatives of N-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
CNB2004800338737A CN100430394C (zh) 2003-10-17 2004-10-15 N-[杂芳基(哌啶-2-基)甲基]苯甲酰胺衍生物及其制备方法和它们的治疗应用
CA002542370A CA2542370A1 (fr) 2003-10-17 2004-10-15 Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
DK04791552T DK1680418T3 (da) 2003-10-17 2004-10-15 Derivater af N-(heteroaryl-(piperidin-2yl)methyl)benzamid, deres fremstilling og deres anvendelse som terapeutika
HK07104622.1A HK1098456B (en) 2003-10-17 2004-10-15 Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
HR20070327T HRP20070327T3 (en) 2003-10-17 2004-10-15 Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
PL04791552T PL1680418T3 (pl) 2003-10-17 2004-10-15 Pochodne N-[heteroarylo(piperydyn-2-ylo)metylo]benzamidu, ich wytwarzanie i zastosowanie ich w lecznictwie
AU2004281215A AU2004281215B2 (en) 2003-10-17 2004-10-15 Derivatives of N-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
MEP-220/08A MEP22008A (en) 2003-10-17 2004-10-15 Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
AT04791552T ATE361923T1 (de) 2003-10-17 2004-10-15 Derivate von n-(heteroaryl(piperidin-2- yl)methyl)benzamid, verfahren zu deren herstellung und deren anwendung in therapeutika
RU2006116887/04A RU2351596C2 (ru) 2003-10-17 2004-10-15 Производные n-[гетероарил(пиперидин-2-ил)метил]бензамида и их применение в терапии
SI200430375T SI1680418T1 (sl) 2003-10-17 2004-10-15 Derivati N-(heteroaril(piperidin-2-il)metil)benzamida, njihova priprava in njihova terapevtska uporaba
PT04791552T PT1680418E (pt) 2003-10-17 2004-10-15 Derivados de n-[heteroaril ( piperidin-2-il)-metil] benzamida, sua preparação e sua aplicação em terapêutica
ES04791552T ES2287782T3 (es) 2003-10-17 2004-10-15 Derivados de n-(heteroaril(piperidin-2-il)metil)benzamida, su preparacion y su aplicacion en terapeutica.
DE602004006431T DE602004006431T2 (de) 2003-10-17 2004-10-15 Derivate von n-äheteroaryl(piperidin-2-yl)methylübenzamid, verfahren zu deren herstellung und deren anwendung in therapeutika
JP2006534798A JP4696069B2 (ja) 2003-10-17 2004-10-15 Ｎ−［ヘテロアリル（ピペリジン−２−イル）メチル］ベンズアミドの誘導体、この調製方法およびこの治療法における使用
YUP-2006/0316A RS20060316A (sr) 2003-10-17 2004-10-15 Derivati n-/heteroaril(piperidin-2-il)metil/benzamida, postupak za njihovo dobijanje i njihova terapeutska primena
EP04791552A EP1680418B1 (fr) 2003-10-17 2004-10-15 Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
IL174941A IL174941A (en) 2003-10-17 2006-04-11 Derivatives of n-[heteroaryl (piperidine-2-yl) methyl] benzamide and pharmaceutical compositions comprising them
MA28942A MA28097A1 (fr) 2003-10-17 2006-04-17 Derives de n-[heteroaryl(piperidin-2-yl)methyl] benzamide, leur preparation et leur application en therapeutique
US11/405,170 US7335670B2 (en) 2003-10-17 2006-04-17 Derivatives of N-[heteroaryl(piperidine-2-yl) methyl]benzamide, preparation method thereof and application of same in therapeutics
NO20062151A NO20062151L (no) 2003-10-17 2006-05-12 Derivater av N-[heteroaryl(piperidin-2-yl)metyl]benzamid, fremgangsmate for fremstilling derav og anvendelse av forbindelsene innenfor terapi
ZA200603941A ZA200603941B (en) 2003-10-17 2006-05-16 Derivatives of N-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
CY20071101037T CY1106786T1 (el) 2003-10-17 2007-08-02 Παραγωγα ν-[ετεροαρυλο(πιπεριδινο-2-υλο)μεθυλο]βενζαμιδιου, η διαδικασια παρασκευης τους και η εφαρμογη τους στη θεραπευτικη

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0312142A FR2861073B1 (fr) 2003-10-17 2003-10-17 Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
FR2861073A1 FR2861073A1 (fr) 2005-04-22
FR2861073B1 true FR2861073B1 (fr) 2006-01-06

Family

ID=34385235

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0312142A Expired - Fee Related FR2861073B1 (fr) 2003-10-17 2003-10-17 Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique

Country Status (26)

Country Link
US (1) US7335670B2 (https=)
EP (1) EP1680418B1 (https=)
JP (1) JP4696069B2 (https=)
KR (1) KR20060087598A (https=)
CN (1) CN100430394C (https=)
AT (1) ATE361923T1 (https=)
AU (1) AU2004281215B2 (https=)
BR (1) BRPI0415452A (https=)
CA (1) CA2542370A1 (https=)
CY (1) CY1106786T1 (https=)
DE (1) DE602004006431T2 (https=)
DK (1) DK1680418T3 (https=)
ES (1) ES2287782T3 (https=)
FR (1) FR2861073B1 (https=)
HR (1) HRP20070327T3 (https=)
IL (1) IL174941A (https=)
MA (1) MA28097A1 (https=)
ME (1) MEP22008A (https=)
NO (1) NO20062151L (https=)
NZ (1) NZ547165A (https=)
PL (1) PL1680418T3 (https=)
PT (1) PT1680418E (https=)
RS (1) RS20060316A (https=)
RU (1) RU2351596C2 (https=)
WO (1) WO2005037781A2 (https=)
ZA (1) ZA200603941B (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842804B1 (fr) 2002-07-29 2004-09-03 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861071B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique
FR2861074B1 (fr) * 2003-10-17 2006-04-07 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
PL1828154T3 (pl) 2004-12-09 2009-10-30 Hoffmann La Roche Pochodne fenylopiperazynometanonu
US20100216837A1 (en) * 2004-12-23 2010-08-26 Glaxo Group Limited Glycine transport inhibitors
PE20061156A1 (es) 2004-12-23 2006-12-16 Glaxo Group Ltd Derivados de benzamida como agentes inhibidores del transportador de glicina
GB0428233D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Compounds
PE20061490A1 (es) * 2005-06-06 2007-02-09 Merck Sharp & Dohme Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
FR2906251B1 (fr) 2006-09-22 2008-11-07 Sanofi Aventis Sa Derives de pyrrolizine, indolizine et quinolizine, leur preparation et leur application en therapeutique
EP1961735B1 (en) * 2007-02-22 2009-11-18 Indena S.P.A. Process for the preparation of (2r,3s)-3-phenylisoserine methyl ester acetate salt
MX2009014235A (es) 2007-08-22 2010-04-27 Abbott Gmbh & Co Kg 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
EP2527328A1 (en) 2008-04-01 2012-11-28 Abbott GmbH & Co. KG Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
WO2010087761A1 (en) * 2009-01-28 2010-08-05 Astrazeneca Ab 2-aza-bicyclo[2.2.2]octane compounds and uses thereof
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
JP5618047B2 (ja) * 2010-01-29 2014-11-05 国立大学法人千葉大学 ポジトロン断層撮影法およびポジトロン放出化合物
KR101180174B1 (ko) * 2010-04-23 2012-09-05 동아제약주식회사 신규한 벤즈아미드 유도체
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8853196B2 (en) 2011-08-05 2014-10-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
CN104011028A (zh) 2011-11-18 2014-08-27 艾伯维德国有限责任两合公司 N-取代的氨基苯并环庚烯、氨基四氢化萘、氨基茚满和苯烷基胺衍生物、包含所述衍生物的药物组合物及其在治疗中的用途
WO2013075624A1 (zh) * 2011-11-22 2013-05-30 北京哈三联科技股份有限公司 甘氨酸重摄取抑制剂及其应用
JP6145109B2 (ja) * 2011-11-29 2017-07-05 ビボゾン インコーポレイテッド 新規のベンズアミド誘導体、及びこの用途
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015055770A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
SG11201602935PA (en) 2013-10-17 2016-05-30 Abbvie Deutschland Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
CN108218846A (zh) * 2016-12-22 2018-06-29 四川海思科制药有限公司 噻吩衍生物的新固态形式及其制备方法和用途
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201903832D0 (en) * 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
KR20220024114A (ko) * 2019-06-20 2022-03-03 주식회사 비보존 수술 후 통증의 예방 또는 치료 방법
CN114478360B (zh) * 2022-02-10 2023-08-15 江苏海洋大学 一种苯甲酰胺类衍生物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254569A (en) * 1991-01-14 1993-10-19 The Du Pont Merck Pharmaceutical Company (Amidomethyl)nitrogen heterocyclic analgesics
JP3026845B2 (ja) * 1991-02-20 2000-03-27 日清製粉株式会社 ピペリジン誘導体
US6319920B1 (en) * 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
EP1296950A2 (en) * 2000-04-20 2003-04-02 NPS Allelix Corp. Aminopiperidines for use as glyt-1 inhibitors
FR2838739B1 (fr) * 2002-04-19 2004-05-28 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique
FR2842804B1 (fr) * 2002-07-29 2004-09-03 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
US20060223886A1 (en) 2006-10-05
ZA200603941B (en) 2007-11-28
IL174941A0 (en) 2006-08-20
JP4696069B2 (ja) 2011-06-08
RU2351596C2 (ru) 2009-04-10
CA2542370A1 (fr) 2005-04-28
FR2861073A1 (fr) 2005-04-22
RU2006116887A (ru) 2007-11-27
MA28097A1 (fr) 2006-08-01
DE602004006431D1 (de) 2007-06-21
PL1680418T3 (pl) 2008-01-31
KR20060087598A (ko) 2006-08-02
JP2007508359A (ja) 2007-04-05
HK1098456A1 (zh) 2007-07-20
ATE361923T1 (de) 2007-06-15
CN1882581A (zh) 2006-12-20
DE602004006431T2 (de) 2008-01-10
RS20060316A (sr) 2008-11-28
WO2005037781A2 (fr) 2005-04-28
AU2004281215A1 (en) 2005-04-28
NO20062151L (no) 2006-05-12
CN100430394C (zh) 2008-11-05
WO2005037781A3 (fr) 2005-07-14
DK1680418T3 (da) 2007-09-10
AU2004281215B2 (en) 2010-09-30
IL174941A (en) 2011-12-29
EP1680418B1 (fr) 2007-05-09
CY1106786T1 (el) 2012-05-23
BRPI0415452A (pt) 2006-12-19
PT1680418E (pt) 2007-08-10
US7335670B2 (en) 2008-02-26
HRP20070327T3 (en) 2007-09-30
MEP22008A (en) 2010-06-10
ES2287782T3 (es) 2007-12-16
EP1680418A2 (fr) 2006-07-19
NZ547165A (en) 2010-01-29

Similar Documents

Publication Publication Date Title
FR2861073B1 (fr) Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861071B1 (fr) Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique
FR2861070B1 (fr) Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique
MA28099A1 (fr) Derives de n-heterocyclymethylbenzamides, leur preparation et leur application en therapeutique
CA2742248C (en) Melanocortin receptor agonists
PE20040993A1 (es) Derivados de taxano y de isotiazol referidos a enfermedades hiperproliferativas
CA2565813A1 (en) Substituted methyl aryl or heteroaryl amide compounds
NZ603724A (en) Piperidine derivatives and their use for the treatment of metabolic disorders
PE20090606A1 (es) Nuevos inhibidores de catepsina c y uso
RU2009117209A (ru) 2-пиридинкарбоксамидное производное, обладающее gk-активирующим действием
JP2005272321A (ja) 含窒素複素環化合物およびその医薬用途
CY1110613T1 (el) Υποκατεστημενες θειαζολες και η χρησιμοποιηση τους για την παρασκευη φαρμακων
PT1789403E (pt) Derivados de n-(fenil-oxazol-4-ilmetoximetil)-ciclo-hexilsuccinamida e compostos relacionados como ligandos dos ppar (receptores activados de proliferadores de peroxisomas) para o tratamento da hiperlipidemia e diabetes
RU2006141276A (ru) Производное пурина
Konaklieva et al. Chemical communication-Do we have a quorum?
KR970005060A (ko) 식물병원균 제어방법
RU2013112560A (ru) Ингибиторы васе для применения в лечении диабета
RU2015131137A (ru) Производное амида коричной кислоты
FR2865208B1 (fr) Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique
RU2007103236A (ru) Бензилокси-производные в качестве ингибиторов моноаминоксидазы б
PE20091945A1 (es) Derivados de 3-oxoisoindolin-1-carboxamida
RU2002132380A (ru) Новые соединения
TH63263A (th) N-[4(1H-อิมิดาซอล-1-อิล)-2-ฟลูออโรฟีนิล]-3-(ไตรฟลูออโรเมทธิล)-1H-ไพราโซล-5-คาร์บอกซาไมด์ ชนิดใหม่ในการเป็นการสารยับยั้งของแฟคเตอร์ Xa

Legal Events

Date Code Title Description
CD Change of name or company name
ST Notification of lapse

Effective date: 20130628